Analysis of prognostic factors for endometrial cancer, taking into account the insulin-like growth factor IGF-1,2, its activation pathway and related genes in the context of the involvement of Forkhead box and FGFR2 proteins in the treatment of endometrial cancer

Aim:
Endometrial cancer (EC) is one of the most common gynecological cancers, and its treatment constitutes a major challenge for modern oncology. The aim of the study was to explore the prognostic factors of endometrial cancer, with particular emphasis on IGF-1,2 and the activation pathway, and to investigate the role of Forkhead box and FGFR2 proteins in key cellular processes related to the development of this cancer.

Material and methods:
The study included 306 Caucasian women diagnosed with confirmed endometrial cancer at the WSZZ in Kielce between 2005 and 2017. The patients underwent total hysterectomy with pelvic lymphadenectomy, computed tomography of the abdomen and chest, typical blood tests and endoscopic examinations. Each case was rediagnosed according to the eighth edition of the TNM classification.

Results:
In 103 patients operated on at the WSZZ in Kielce, further tests were performed on the insulin-like growth factor IGF-1,2, its activation pathway and related genes in the context of the involvement of Forkhead box and FGFR2 proteins.

Conclusions:
1. The FGFR-2 receptor plays an important role in the diagnosis of endometrial cancer, suggesting the possibility of using it to determine the prognosis and treatment of patients 2. FOX protein has an established role in regulating tumor growth, but its interaction with other genes such as TP53 and KRAS remains unclear. 3.The study confirms EMT as an important biomarker for EC prediction. 4. Mutation in the FGFR-2 gene may affect EMT and indirectly affect the prognosis in patients with EC.